Mayne Pharma Group Ltd
ASX:MYX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.81
7.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd
Total Equity
Mayne Pharma Group Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$454.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Total Equity
-AU$9.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$219.2m
|
CAGR 3-Years
136%
|
CAGR 5-Years
67%
|
CAGR 10-Years
26%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Total Equity
AU$108.7m
|
CAGR 3-Years
74%
|
CAGR 5-Years
181%
|
CAGR 10-Years
47%
|
|
|
Probiotec Ltd
ASX:PBP
|
Total Equity
AU$88.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Total Equity
AU$11.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Mayne Pharma Group Ltd
Glance View
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
See Also
What is Mayne Pharma Group Ltd's Total Equity?
Total Equity
454.2m
AUD
Based on the financial report for Jun 30, 2024, Mayne Pharma Group Ltd's Total Equity amounts to 454.2m AUD.
What is Mayne Pharma Group Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-15%
Over the last year, the Total Equity growth was -28%. The average annual Total Equity growth rates for Mayne Pharma Group Ltd have been -16% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
